EP 1408947 A2 20040421 - FUMARIC ACID DERIVATIVES AS NF-KAPPAB INHIBITORS
Title (en)
FUMARIC ACID DERIVATIVES AS NF-KAPPAB INHIBITORS
Title (de)
FUMARSÄUREDERIVATE ALS NF-KAPPAB-INHIBITOREN
Title (fr)
DERIVES DE L'ACIDE FUMARIQUE UTILISES COMME INHIBITEURS NF-KAPPAB
Publication
Application
Priority
- DE 10101307 A 20010112
- EP 0200108 W 20020108
Abstract (en)
[origin: WO02055067A2] The invention relates to the use of at least one fumaric acid derivative as an NF-kappaB inhibitor. The invention also relates to the use of fumaric acid derivatives for producing a pharmaceutical preparation for the treatment of disorders which can be influenced by NF-kappaB.
IPC 1-7
A61K 31/194; A61K 31/225; A61P 1/04; A61P 1/16; A61P 9/00; A61P 11/00; A61P 13/12; A61P 17/00; A61P 19/02; A61P 19/06; A61P 31/00; A61P 35/00
IPC 8 full level
A61K 9/16 (2006.01); A61K 9/20 (2006.01); A61K 9/28 (2006.01); A61K 9/48 (2006.01); A61K 9/50 (2006.01); A61K 9/62 (2006.01); A61K 31/194 (2006.01); A61K 31/225 (2006.01); A61K 47/04 (2006.01); A61K 47/12 (2006.01); A61K 47/32 (2006.01); A61K 47/36 (2006.01); A61K 9/22 (2006.01); A61K 47/38 (2006.01); A61P 1/04 (2006.01); A61P 1/16 (2006.01); A61P 9/00 (2006.01); A61P 9/10 (2006.01); A61P 11/00 (2006.01); A61P 13/12 (2006.01); A61P 17/00 (2006.01); A61P 19/02 (2006.01); A61P 19/06 (2006.01); A61P 19/08 (2006.01); A61P 25/00 (2006.01); A61P 31/00 (2006.01); A61P 31/04 (2006.01); A61P 31/12 (2006.01); A61P 35/00 (2006.01); A61P 39/02 (2006.01)
CPC (source: EP US)
A61K 9/1652 (2013.01 - EP US); A61K 9/2059 (2013.01 - EP US); A61K 9/2846 (2013.01 - EP US); A61K 9/4808 (2013.01 - EP US); A61K 9/5026 (2013.01 - EP US); A61K 31/194 (2013.01 - EP US); A61K 31/225 (2013.01 - EP US); A61P 1/00 (2018.01 - EP); A61P 1/04 (2018.01 - EP); A61P 1/16 (2018.01 - EP); A61P 1/18 (2018.01 - EP); A61P 3/10 (2018.01 - EP); A61P 9/00 (2018.01 - EP); A61P 9/10 (2018.01 - EP); A61P 11/00 (2018.01 - EP); A61P 13/10 (2018.01 - EP); A61P 13/12 (2018.01 - EP); A61P 17/00 (2018.01 - EP); A61P 19/00 (2018.01 - EP); A61P 19/02 (2018.01 - EP); A61P 19/06 (2018.01 - EP); A61P 19/08 (2018.01 - EP); A61P 25/00 (2018.01 - EP); A61P 27/02 (2018.01 - EP); A61P 31/00 (2018.01 - EP); A61P 31/04 (2018.01 - EP); A61P 31/12 (2018.01 - EP); A61P 35/00 (2018.01 - EP); A61P 35/02 (2018.01 - EP); A61P 39/02 (2018.01 - EP); A61P 43/00 (2018.01 - EP)
Designated contracting state (EPC)
AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR
DOCDB simple family (publication)
WO 02055067 A2 20020718; WO 02055067 A3 20040226; AU 2002244638 B2 20050505; BG 107829 A 20041230; BR 0206381 A 20040803; CA 2428075 A1 20020718; CN 1520291 A 20040811; CZ 20031918 A3 20040414; DE 10101307 A1 20020801; EE 200300281 A 20031015; EP 1408947 A2 20040421; HU P0302650 A2 20031128; HU P0302650 A3 20090828; IL 156849 A0 20040208; JP 2004528281 A 20040916; JP 2009073854 A 20090409; MX PA03006248 A 20040402; NO 20031450 D0 20030328; NO 20031450 L 20030912; NZ 525148 A 20060630; PL 363603 A1 20041129; RU 2003124751 A 20050110; RU 2282440 C2 20060827; SK 8252003 A3 20031202; US 2004054001 A1 20040318; US 2008233185 A1 20080925; WO 02055066 A1 20020718; YU 55903 A 20060817; ZA 200305343 B 20040817
DOCDB simple family (application)
EP 0200108 W 20020108; AU 2002244638 A 20020108; BG 10782903 A 20030520; BR 0206381 A 20020108; CA 2428075 A 20020108; CN 02803628 A 20020108; CZ 20031918 A 20020108; DE 10101307 A 20010112; EE P200300281 A 20020108; EP 0104454 W 20010419; EP 02712806 A 20020108; HU P0302650 A 20020108; IL 15684902 A 20020108; JP 2002555801 A 20020108; JP 2008290821 A 20081113; MX PA03006248 A 20020108; NO 20031450 A 20030328; NZ 52514802 A 20020108; PL 36360302 A 20020108; RU 2003124751 A 20020108; SK 8252003 A 20020108; US 25098303 A 20030710; US 83315007 A 20070802; YU P55903 A 20020108; ZA 200305343 A 20030710